GSK 1070806

Drug Profile

GSK 1070806

Alternative Names: 1070806; GSK-1070806

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 18 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Delayed graft function
  • Discontinued Inflammatory bowel diseases; Metabolic disorders; Type 2 diabetes mellitus

Most Recent Events

  • 01 Aug 2016 Phase-II clinical trials in Delayed graft function (Prevention) in United Kingdom (IV)
  • 24 Mar 2016 GlaxoSmithKline plans a phase II trial for Delayed graft function (Prevention, Combination therapy) in USA and United Kingdom (IV) (NCT02723786)
  • 01 Jan 2014 GlaxoSmithKline completes a phase II trial in Type-2 diabetes mellitus in United Kingdom and Spain (NCT01648153)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top